Fundz

Rosemont to acquire Aytu BioPharma for $2.70/sh

PRIVATENov 17, 2026

Acquiring Company

Rosemont Pharmaceuticals

Acquired Company

Aytu BioPharma

United KingdomDenverBiotechnologyPharmaceuticalHealthcare

Description

Rosemont Pharmaceuticals has entered a definitive merger agreement to acquire Aytu BioPharma through a tender offer at $2.70 per share in cash, a 41.1 per cent premium to Aytu's 30-day VWAP. The deal was unanimously approved by Aytu's board, with completion anticipated in late December 2026, subject to conditions. The acquisition will be followed by a second-step merger at the same price and supports Rosemont's US specialty pharmaceutical expansion.

Quick answer

Rosemont Pharmaceuticals is acquiring Aytu BioPharma, announced November 17, 2026. Rosemont Pharmaceuticals is based in United Kingdom.

How much did Rosemont Pharmaceuticals pay for Aytu BioPharma?
The deal value was not disclosed.
What does Rosemont Pharmaceuticals do?
Rosemont Pharmaceuticals is a specialty pharmaceutical company expanding its international and US specialty medicines business.
Where are Rosemont Pharmaceuticals and Aytu BioPharma based?
Rosemont Pharmaceuticals is based in United Kingdom. Aytu BioPharma is based in Denver, Colorado, United States.

Source: Fundz verified event record.

Other recent acquisitions in Pharmaceutical and Healthcare

Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.

Who to call at Rosemont Pharmaceuticals, and when

When Rosemont Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Rosemont Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Rosemont Pharmaceuticals, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Rosemont Pharmaceuticals. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Rosemont Pharmaceuticals

Location

United Kingdom

About

Rosemont Pharmaceuticals is a specialty pharmaceutical company expanding its international and US specialty medicines business. It is backed by Inflexion, a European mid-market private equity firm.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Rosemont Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Rosemont Pharmaceuticals's next move

Learn about Strategic plan

Frequently asked

Who acquired Aytu BioPharma?

Aytu BioPharma was acquired by Rosemont Pharmaceuticals, based in United Kingdom. The deal was reported on November 17, 2026. Rosemont Pharmaceuticals is a specialty pharmaceutical company expanding its international and US specialty medicines business. It is backed by Inflexion, a European mid-market private equity firm. Rosemont Pharmaceuticals is privately held and operates in Biotechnology.

When did Rosemont Pharmaceuticals acquire Aytu BioPharma?

Rosemont Pharmaceuticals's acquisition of Aytu BioPharma was reported on November 17, 2026. Rosemont Pharmaceuticals has entered a definitive merger agreement to acquire Aytu BioPharma through a tender offer at $2.70 per share in cash, a 41.1 per cent premium to Aytu's 30-day VWAP. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Aytu BioPharma do?

Aytu BioPharma, Inc. is a biopharmaceutical company that focuses on developing and commercializing novel products in the field of men's health, women’s health, and other underserved patient populations. It is publicly traded (AYTU), operating in Healthcare, and is based in Denver.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.